To enact section 3902.65 of the Revised Code to prohibit certain insurance practices related to physician-administered drugs for patients with chronic, complex, rare, or life-threatening medical conditions.
HB682 would add a new section to Ohio insurance law restricting certain health benefit plan practices involving physician-administered drugs when those drugs are given on an outpatient basis in a physician’s office or an independent hospital. For covered persons with chronic, complex, rare, or life-threatening conditions, the bill would bar plans from requiring that these drugs be dispensed only through certain pharmacies or in-network pharmacies, from denying or limiting coverage based on the pharmacy used, and from forcing providers to bill under the pharmacy benefit instead of the medical benefit unless the patient gives informed consent and the provider attests that delay would not increase health risk. It would also prohibit extra fees or higher cost-sharing tied to pharmacy choice or network status.
The bill applies only when a physician or other health care provider determines that delay in care would likely worsen disease, that use of an in-network pharmacy could create a risk of harm or interfere with compliance, or that a different pharmacy is needed because of timing or dosage needs. It also makes clear that it does not change existing state law on who may administer drugs or the supervision and delegation rules for drug administration. The effective date structure would apply these restrictions to health benefit plans issued, amended, or renewed on or after January 1, 2027.
HB682 would create a new insurance coverage rule in the Revised Code, limiting how health plan issuers can manage physician-administered drugs through pharmacy network restrictions, benefit design, and cost-sharing. In practice, it would protect access to certain specialty or medically necessary drugs for patients with serious conditions and would affect insurers, pharmacies, physicians, hospitals, and covered persons by shifting some utilization-management authority away from pharmacy-benefit controls in specified outpatient settings.
The bill appears to be framed as a patient-access measure, with its text emphasizing timely treatment, avoidance of harm, and continuity of care for vulnerable patients. Because the bill was only introduced and no committee testimony or votes are provided, there is no recorded public debate in the materials. The available context suggests a generally supportive policy purpose centered on reducing barriers to treatment rather than on cost containment.
The main policy tension in HB682 is between patient access and insurer/pharmacy benefit management practices. Supporters would likely view the bill as preventing delays, network restrictions, and administrative barriers for patients with serious illnesses, while potential opponents may be concerned that it limits insurers’ ability to steer utilization, manage costs, or require use of preferred pharmacies. Another possible point of contention is the bill’s reliance on physician determinations and informed consent/attestation requirements, which could raise questions about implementation and documentation.